Methylation Mediated Silencing of TMS1/ASC Gene in Prostate Cancer

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2006 Jul 20

PMID 16848908

Citations 55

Authors

Partha M Das

Kavitha Ramachandran

Jane Vanwert

Larry Ferdinand

Gopal Gopisetty

Isildinha M Reis

Rakesh Singal

Affiliations

Soon will be listed here.

Abstract

Background: Transcriptional silencing associated with aberrant promoter methylation has been established as an alternate pathway for the development of cancer by inactivating tumor suppressor genes. TMS1 (Target of Methylation induced Silencing), also known as ASC (Apoptosis Speck like protein containing a CARD) is a tumor suppressor gene which encodes for a CARD (caspase recruitment domain) containing regulatory protein and has been shown to promote apoptosis directly and by activation of downstream caspases. This study describes the methylation induced silencing of TMS1/ASC gene in prostate cancer cell lines. We also examined the prevalence of TMS1/ASC gene methylation in prostate cancer tissue samples in an effort to correlate race and clinico-pathological features with TMS1/ASC gene methylation.

Results: Loss of TMS1/ASC gene expression associated with complete methylation of the promoter region was observed in LNCaP cells. Gene expression was restored by a demethylating agent, 5-aza-2'deoxycytidine, but not by a histone deacetylase inhibitor, Trichostatin A. Chromatin Immunoprecipitation (ChIP) assay showed enrichment of MBD3 (methyl binding domain protein 3) to a higher degree than commonly associated MBDs and MeCP2. We evaluated the methylation pattern in 66 prostate cancer and 34 benign prostatic hyperplasia tissue samples. TMS1/ASC gene methylation was more prevalent in prostate cancer cases than controls in White patients (OR 7.6, p 0.002) while no difference between the cases and controls was seen in Black patients (OR 1.1, p 0.91).

Conclusion: Our study demonstrates that methylation-mediated silencing of TMS1/ASC is a frequent event in prostate cancer, thus identifying a new potential diagnostic and prognostic marker for the treatment of the disease. Racial differences in TMS1/ASC methylation patterns implicate the probable role of molecular markers in determining in susceptibility to prostate cancer in different ethnic groups.

Citing Articles

gene polymorphisms and susceptibility to periodontal and coronary heart diseases.

Daily Z, Al-Ghurabi B, Al-Qarakhli A J Med Life. 2024; 17(2):195-200.

PMID: 38813354 PMC: 11131647. DOI: 10.25122/jml-2023-0263.

Epigenetic (De)regulation in Prostate Cancer.

Xu C, Zhao S, Cai L Cancer Treat Res. 2023; 190:321-360.

PMID: 38113006 PMC: 11421856. DOI: 10.1007/978-3-031-45654-1_10.

Genetic and biological drivers of prostate cancer disparities in Black men.

Gong J, Kim D, Freeman M, Kim H, Ellis L, Smith B Nat Rev Urol. 2023; 21(5):274-289.

PMID: 37964070 DOI: 10.1038/s41585-023-00828-w.

Comparative and integrative analysis of transcriptomic and epigenomic-wide DNA methylation changes in African American prostate cancer.

Creighton C, Zhang F, Zhang Y, Castro P, Hu R, Islam M Epigenetics. 2023; 18(1):2180585.

PMID: 37279148 PMC: 9980641. DOI: 10.1080/15592294.2023.2180585.

Expression of NLRP3 and AIM2 inflammasome in Peripheral blood in Chinese patients with acute and chronic brucellosis.

Su X, Zhao S, Song Y Sci Rep. 2022; 12(1):15123.

PMID: 36068262 PMC: 9448728. DOI: 10.1038/s41598-022-19398-9.

References

Fang M, Chen D, Sun Y, Jin Z, Christman J, Yang C . Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res. 2005; 11(19 Pt 1):7033-41. DOI: 10.1158/1078-0432.CCR-05-0406. View

Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H . Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res. 2005; 3(6):325-34. DOI: 10.1158/1541-7786.MCR-04-0105. View

McConnell B, Vertino P . Activation of a caspase-9-mediated apoptotic pathway by subcellular redistribution of the novel caspase recruitment domain protein TMS1. Cancer Res. 2000; 60(22):6243-7. View

Esteller M, Corn P, Baylin S, Herman J . A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61(8):3225-9. View

Stimson K, Vertino P . Methylation-mediated silencing of TMS1/ASC is accompanied by histone hypoacetylation and CpG island-localized changes in chromatin architecture. J Biol Chem. 2001; 277(7):4951-8. DOI: 10.1074/jbc.M109809200. View

Manji G, Wang L, Geddes B, Brown M, Merriam S, Al-Garawi A . PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B. J Biol Chem. 2002; 277(13):11570-5. DOI: 10.1074/jbc.M112208200. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Grenier J, Wang L, Manji G, Huang W, Al-Garawi A, Kelly R . Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB and caspase-1. FEBS Lett. 2002; 530(1-3):73-8. DOI: 10.1016/s0014-5793(02)03416-6. View

Stehlik C, Fiorentino L, Dorfleutner A, Bruey J, Ariza E, Sagara J . The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. J Exp Med. 2002; 196(12):1605-15. PMC: 2196065. DOI: 10.1084/jem.20021552. View

10.

Laird P . The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003; 3(4):253-66. DOI: 10.1038/nrc1045. View

11.

Woodson K, Hayes R, Wideroff L, Villaruz L, Tangrea J . Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate. 2003; 55(3):199-205. DOI: 10.1002/pros.10236. View

12.

Virmani A, Rathi A, Sugio K, Sathyanarayana U, Toyooka S, Kischel F . Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer. Int J Cancer. 2003; 106(2):198-204. DOI: 10.1002/ijc.11206. View

13.

Guan X, Sagara J, Yokoyama T, Koganehira Y, Oguchi M, Saida T . ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma. Int J Cancer. 2003; 107(2):202-8. DOI: 10.1002/ijc.11376. View

14.

Ballestar E, Paz M, Valle L, Wei S, Fraga M, Espada J . Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 2003; 22(23):6335-45. PMC: 291845. DOI: 10.1093/emboj/cdg604. View

15.

Yokoyama T, Sagara J, Guan X, Masumoto J, Takeoka M, Komiyama Y . Methylation of ASC/TMS1, a proapoptotic gene responsible for activating procaspase-1, in human colorectal cancer. Cancer Lett. 2003; 202(1):101-8. DOI: 10.1016/j.canlet.2003.08.027. View

16.

McConnell B, Vertino P . TMS1/ASC: the cancer connection. Apoptosis. 2004; 9(1):5-18. DOI: 10.1023/B:APPT.0000012117.32430.0c. View

17.

Strathdee G, Brown R . Aberrant DNA methylation in cancer: potential clinical interventions. Expert Rev Mol Med. 2004; 4(4):1-17. DOI: 10.1017/S1462399402004222. View

18.

Woodson K, Hanson J, Tangrea J . A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett. 2004; 205(2):181-8. DOI: 10.1016/j.canlet.2003.11.027. View

19.

Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A . Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res. 2004; 10(6):2000-6. DOI: 10.1158/1078-0432.ccr-0932-03. View

20.

Zhu Y, Harrison D, Bader S . Genetic and epigenetic analyses of MBD3 in colon and lung cancer. Br J Cancer. 2004; 90(10):1972-5. PMC: 2410281. DOI: 10.1038/sj.bjc.6601776. View